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Compromised secretory function of choroid plexus (CP) and defective cerebrospinal fluid
(CSF) production, along with accumulation of beta-amyloid (Aβ) peptides at the blood-CSF
barrier (BCSFB), contribute to complications of Alzheimer’s disease (AD). The AD triple
transgenic mouse model (3xTg-AD) at 16 month-old mimics critical hallmarks of the human
disease: β-amyloid (Aβ) plaques and neurofibrillary tangles (NFT) with a temporal- and
regional- specific profile. Currently, little is known about transport and metabolic responses
by CP to the disrupted homeostasis of CNS Aβ in AD. This study analyzed the effects of
highly-expressed AD-linked human transgenes (APP, PS1 and tau) on lateral ventricle CP
function. Confocal imaging and immunohistochemistry revealed an increase only of Aβ42
isoform in epithelial cytosol and in stroma surrounding choroidal capillaries; this buildup
may reflect insufficient clearance transport from CSF to blood. Still, there was increased
expression, presumably compensatory, of the choroidal Aβ transporters: the low density
lipoprotein receptor-related protein 1 (LRP1) and the receptor for advanced glycation end
product (RAGE). A thickening of the epithelial basal membrane and greater collagen-
IV deposition occurred around capillaries in CP, probably curtailing solute exchanges.
Moreover, there was attenuated expression of epithelial aquaporin-1 and transthyretin
(TTR) protein compared to Non-Tg mice. Collectively these findings indicate CP dysfunction
hypothetically linked to increasing Aβ burden resulting in less efficient ion transport,
concurrently with reduced production of CSF (less sink action on brain Aβ) and diminished
secretion of TTR (less neuroprotection against cortical Aβ toxicity). The putative effects of
a disabled CP-CSF system on CNS functions are discussed in the context of AD.
Keywords: Alzheimer disease, 3xTg-AD mice, choroid plexus, dysfunction, amyloid-β, collagen-IV, transthyretin,
aquaporin-1
INTRODUCTION
Alzheimer’s disease (AD) is age-related neurodegeneration
characterized by plaques that consist mainly of amyloid-β
(Aβ) peptides and neurofibrillary tangles (NFT) containing
hyperphosphorylated tau protein. These protein distortions
contribute to disrupted synapses and neurotransmission,
progressive neuronal death, memory impairment, and cognitive
disturbances (Church et al., 2014). In vitro and in vivo studies
suggest that excessive Aβ peptides, at least in part, are causative or
exacerbative agents in AD pathogenesis (Wang et al., 2006). Brain
Aβ peptides of 40 (Aβ40) or 42 (Aβ42) amino acids are produced,
with Aβ42 being more aggregation prone (Thinakaran and Koo,
2008).
Aβ peptides are generated from transmembrane amyloid
precursor protein (APP) by β-secretase and γ-secretase in
the endoplasmic reticulum, Golgi apparatus, and endosomal-
lysosomal pathway (Selkoe, 2001; LaFerla et al., 2007). This
Aβ-producing amyloidogenic pathway is active when APP has
mutations at the cleavage sites by β- secretase or γ-secretase
(Haass et al., 1995; Wolfe et al., 1999). In contrast, α-secretase
cleaves APP within the Aβ domain, precluding the generation
of Aβ in normal APP metabolism. While extracellular Aβ
aggregation has long been considered as a key culprit in AD
onset, intracellular Aβ accumulation is detected in neurons
prior to the appearance of extracellular deposits (Wirths et al.,
2001; Youmans et al., 2012) and is associated with cytotoxicity,
dysfunction of organelles, and neurodegeneration (Bayer and
Wirths, 2010).
While the rare autosomal dominant familial AD is mostly due
to overproduction of Aβ (O’Brien and Wong, 2011) or enhancing
Aβ protofibril formation, far more common is the late-onset
sporadic AD (sAD), thought to be caused, in part, by decreased
clearance of the Aβ peptide from the CNS (Dorfman et al., 2010;
Mawuenyega et al., 2010; Silverberg et al., 2010a). Thus, the
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deregulation of Aβ clearance pathways in brain and at CP-CSF
may be a central disease event in some AD cases.
Maintenance of equilibrium in volume and composition of
CSF is vital for normal brain function, ensuring an optimal
environment for neurons. Thus the choroid plexus (CP) part
of the blood cerebrospinal fluid barrier (BCSFB) also mediates
secretion of proteins and various processes that clear substances
from the CSF, blood or vice versa (Balda and Matter, 1998;
Al-Sarraf et al., 2007; González-Marrero et al., 2013). CP has
traditionally been associated with active secretion of CSF into
the cerebral ventricles. Secretion of CSF is a cardinal function
of CP. In CNS, AQP-1, a water channel for high osmotic water
permeability, is expressed mainly in the apical membrane of the
ventricular CP (Boassa and Yool, 2005) and regulates formation
of CSF. Noteworthy, >90% of the transthyretin (TTR) in CSF is
synthesized within CP (Serot et al., 1997). TTR is the hallmark
protein synthesized by CP; its level in the epithelium and CSF
reflect the health of the BCSFB. The main carriers for Aβ
transport across BBB from brain-to-blood, and blood-to-brain,
are lipoprotein receptor-related protein (LRP1) and the receptor
for advanced glycation end-products (RAGE), respectively. Aβ
transporters in BBB endothelium are also found in CP epithelium,
e.g., LRP1 (Pascale et al., 2011), megalin/LRP2, P-gp and RAGE
(Hammad et al., 1997; Deane et al., 2003; Serot et al., 2003a;
Crossgrove et al., 2005).
Continuous removal of Aβ species from CNS is important
for preventing potentially neurotoxic accumulation in brain
interstitial fluid (ISF) and CP. Since CP directly connects CSF
with the ISF, the Aβ in the brain extracellular space can freely
enter CSF and be transported at the BCSFB. Increasing data for
animals support the notion that compromised function of CP and
defective CSF production and turnover (Chiu et al., 2012), with
diminished clearance of the Aβ peptides normally produced in
brain, may be a mechanism implicated in the exacerbation of sAD
(Silverberg et al., 2001, 2003; Serot et al., 2003b; Johanson et al.,
2008; Wostyn et al., 2011).
Much understanding of how Aβ pathology develops has been
driven by studies in animal models, which lacks proper reflection
of the human disease, e.g., choroidal transport mechanisms and
CSF homeostasis (Johanson et al., 2004; Spector and Johanson,
2013). Although there is no model capturing all the hallmarks of
AD, it is possible to model Aβ deposition (albeit with cautionary
limitations) when comparing to human metabolic and transport
counterparts. The most popular animal models of AD are
transgenic mice expressing human genes with mutations leading
to familial AD.
Adult 3xTg-AD mice, harboring PS1/M146V, APPSwe and
tauP301L human transgenes, is an animal model that mimics
many critical hallmarks of AD (Oddo et al., 2003b). Adult 3xTg-
AD displays cognitive deficits and other behavioral alterations at
ages when overt neuropathology is not yet observed, although
intraneuronal amyloid Aβ-peptide accumulation and synaptic
(cholinergic) deficits are already being described at 6 months
of age (Oddo et al., 2003b; Hedberg et al., 2010; Sterniczuk
et al., 2010). Adult 3xTg-AD progressively develops Aβ plaques
and NFT from 12 months, with temporal- and regional-
specific profiles closely imitating their development in human
AD (Oddo et al., 2003a,b). Currently, little is known about
the spectrum of transporter and metabolic responses by CP
to the disrupted CNS homeostasis in AD; or reciprocally,
how CP malfunctions may contribute to (exacerbate) AD
neuropathology.
We have sought to determine whether the pathological
accumulation of CNS Aβ in 3xTg-AD mice have repercussions
in the functional protein expression of CP. Moreover, because
compromised metabolic functions of CP and defective CSF
production (turnover) may be linked to worsening sAD, we
decided to ascertain whether 3xTg-AD is useful to study the role
of CP in AD.
MATERIALS AND METHODS
ANIMAL MODEL OF AD
3xTg-AD mice harboring three mutant genes: beta-APP
(APPswe), presenilin-1 (PS- 1M146V) and tauP301L, and the
corresponding wild type mice were provided by Dr. Lydia
Giménez-Llort (Autonomous University of Barcelona, Spain).
Eight 3xTg-AD mice and eight non-transgenic control mice
(Non-Tg), 16 month-old, were used. Tail DNA from WT
and 3xTg-AD mice was genotyped to confirm the absence
or presence of APP, PS1 and tau transgenes in Non-Tg and
3xTg-AD mice, respectively. Moreover the presence of senile
plaques in hippocampus and cerebral cortex was confirmed
by Congo red and thioflavin-S. Mice were kept at a constant
temperature of 21 ± 2◦C and 55 ± 8% relative humidity in
light-dark 12–12 h. All experiments were conducted according to
the European Directive 2010/69/EU for the maintenance and use
of laboratory animals, which were approved by the Committee
of Animal Use for Research at the University of La Laguna.
The number of animals used, as well as stress and suffering
of these subjects during handling and experimentation was
minimized.
IMMUNOFLUORESCENCE
To study lateral ventricle CP, confocal microscopy was used.
Brains were perfused transcardially by PBS 0.1 M followed by
fixative (4% paraformaldehyde in PBS 0.1 M pH 7.4), embedded
in paraffin and sectioned at 7 µm. After deparaffinization and
rehydration, tissue sections were treated with 10 mM citrate
buffer, pH 6, at 85◦C for 20 min. Slides were treated 30 min
with PBS containing 3% bovine serum albumin to block non-
specific binding. After washing in PBS 0.1 M pH 7.4, sections were
incubated overnight at 4◦C with appropriate primary antibody:
rabbit polyclonal anti- amyloid-β 1–40 (ABCAM, 1:500);
rabbit polyclonal anti-amyloid-β 1–42 (Abbiotec, 1:200); rabbit
polyclonal anti-low density LRP1 (Sigma-Aldrich, 1:200); rabbit
polyclonal anti-receptor for advanced glycation end-products
(Sigma-Aldrich, 1:400); rabbit monoclonal anti-aquaporin 1
(ABCAM, 1:200); rabbit polyclonal anti-transthyretin (Dako,
1:200). After washing, Cyanine 3 (Cy3) (red) goat anti-rabbit
IgG conjugate antibodies (Invitrogen) were used as secondary
antibodies for immunofluorescence. Nuclei were stained with 4’-
6’ diamidino-2-phenylindole (DAPI). After 3 washes, samples
were mounted in Vectashield Medium (Vector Laboratories Inc)
for viewing by confocal microscopy (FV 1000 Olympus).
Frontiers in Cellular Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 17 | 2
González-Marrero et al. Choroid plexus dysfunction in 3xTg-AD mice
COLLAGEN-IV IMMUNOHISTOCHEMISTRY
CP collagen-IV was studied using light microscopy. Sections
were treated as explained for confocal microscopy, but after hot
citrate buffer they were washed with distilled water and quenched
with 3% hydrogen peroxide for 10 min at room temperature to
eliminate endogenous peroxidase activity. As a primary antibody,
rabbit polyclonal anti-collagen type IV (ABCAM, 1:500) was
used. Goat anti-rabbit IgG conjugate antibodies (Invitrogen)
were used as secondary antibodies. In light microscopy, the
DAKO StreptABC complex/HRP Duet, Mouse/Rabbit procedure
was used and the peroxidase reaction product visualized with
diaminobenzidine.
QUANTIFICATION OF IMMUNOSTAINING
From each animal/group we obtained near 60 slices of CP of
lateral ventricle. To study each antibody we used 7–8 slices. The
intensity of immunostaining was measured in whole CP present
in the slice. Fluorescence intensities from images were semi-
quantitatively analyzed by densitometry. Immunohistochemistry
slides were converted to digital images by using an LEICA DMRB
photomicroscope with an LEICA DC 300 F camera (Germany)
as 8-bit acquisitions of color. Image analysis was completed in
Image J (v. 1.43 u, NIH, Bethesda, MD, USA). The “Mean
Gray Value” was measured for all stained tissue. This value gives
the average stain intensity in gray scale units for all threshold
pixels.
STATISTICAL ANALYSIS
A one-way ANOVA was used for data comparison between 3xTg-
AD and Non-Tg mice. ANOVA was conducted with IBM SPSS
statistic 19 software where data were considered as statistically
significant at p< 0.01.
RESULTS
AMYLOID-BETA DISTRIBUTION IN CP OF 3xTg-AD AND NON-Tg MICE
Aβ is a short peptide generated from APP with two main
breakdown products, Aβ40 and Aβ42. Here we examined these
peptides in different compartments related to CP in 3xTg-AD
and Non-Tg mice. Also is included a schematic summary of their
distribution in lateral ventricles, epithelial cells, stroma and blood
vessels (Figure 1E).
Confocal microscopy images revealed a strong staining of
stroma and vessels of CP and a moderate cytosolic signal with
anti-Aβ40 (Figures 1A,B). We found reduced Aβ40 expression
in cytosol, stroma and vessels of CP of 3xTg-AD vs. Non-Tg
mice. The difference observed in Aβ40 staining was greater in
the stroma surrounding blood vessels than in CP epithelium. A
reduced Aβ40 expression was detected in CP stroma surrounding
blood vessels and in CP epithelium from 3xTg-AD vs. Non-Tg
mice (Figure 1F; ∗ p< 0.01 3xTg-AD vs. Non-Tg mice).
Regarding Aβ42, staining revealed differences in signal
strength and distribution. Non-Tg mice presented a CP
epithelium with Aβ42 mainly cytoplasmic and specially in areas
near the apical pole (Figure 1C); in 3xTg-AD mice, Aβ42
distributed uniformly through out the cytosol (Figure 1D). Is also
important to point out that Aβ42 had a more than a two-fold
increased expression in stroma of 3xTg-AD mice compared to the
weak expression in Non-Tg mice (Figure 1F; ∗ p< 0.01 3xTg-AD
vs. Non-Tg mice). Also, vessels lacked Aβ42 staining in Non-Tg
animals (Figure 1C).
LRP1 AND RAGE EXPRESSION IN CP EPITHELIUM
LRP1 and RAGE are the main carriers for Aβ transport across BBB
from brain-to-blood, and blood-to-brain, respectively. Therefore,
the next step was to analyze expression of these transporters in
CP of the 3xTg-AD and Non-Tg mice. LRP1 was expressed on
cytoplasm of epithelial cells in Non-Tg animals (Figure 2A) and
in 3xTg-AD mice (Figure 2B). Cytosolic LRP1 protein presented
a two-fold increase in 3xTg-AD compared Non-Tg (Figure 2E).
Confocal microscopy images for RAGE in CP from Non-Tg and
3xTg-AD mice are also shown (Figures 2C,D). The location of
RAGE staining in both groups of animals was only cytosolic and
lacked detection either in CP vessels or basement membrane
(Figures 2C,D). We found ∼four-fold cytoplasmic increase in
RAGE expression in epithelial cells of 3xTg-AD vs. Non-Tg
(Figure 2E; ∗ p< 0.01 3xTg-AD vs. Non- Tg mice).
COLLAGEN-IV DEPOSITION IN CP BASEMENT MEMBRANE
CP is a highly vascularized structure receiving 5–10 times more
blood flow than other brain regions (Szmydynger-Chodobska
et al., 1994). This physiologic state of brisk blood flow would
make CP more sensitive to reduced vascular perfusion. In order
to link possible changes in CBF with the state of both of the
vessels and basement membrane, we also examined collagen-IV
expression. Figure 3 presents CP staining with anti-collagen type
IV in Non-Tg (Figures 3A,B) and 3xTg-AD mice (Figures 3C,D).
Collagen-IV is widely located only in CP epithelial cells basement
membrane and the blood vessel basement membrane, a collagen-
IV cell staining lacked detection in whole CP. Collagen-IV
labeling was ∼two-fold higher in 3xTg-AD in comparison with
Non-Tg mice (Figure 3E; ∗ p < 0.01 3xTg-AD vs. Non- Tg
mice).
AQP-1 AND TTR EXPRESSION IN CP
In AD, the adverse effects of CSF stasis (decreased turnover rate)
are potentiated by declining ability of CSF to inhibit formation
of Aβ oligomers (Serot et al., 2003b, 2012; Silverberg et al., 2003;
Wostyn et al., 2011). We assessed expression of two proteins in
CP secretory functions. These are TTR, one of the major proteins
synthetized by CP, and AQP-1, a water channel transport protein
involved in CSF production. TTR was located in cytoplasm of CP
epithelial cells as in 3xTg-AD as in Non-Tg mice. TTR present in
CP was significantly reduced in 3xTg-AD compared to Non-Tg
mice (Figures 4A,B). This expression was >3 fold lower in 3xTg-
AD than Non-Tg (Figure 4E; ∗ p < 0.01 3xTg-AD vs. Non- Tg
mice).
AQP-1 expression was located on the apical membrane
of CP epithelial cells in Non-Tg (Figure 4C) and 3xTg-AD
mice (Figure 4D). While in Non-Tg mice AQP-1 staining was
distributed in whole apical pole of CP epithelial cells, we observed
that some epithelial cells showed a lack of AQP-1 expression on
their apical membranes. The values of AQP-1 staining were 31%
lower in 3xTg-AD compared to Non-Tg mice (Figure 4E).
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FIGURE 1 | Choroid plexus (CP) confocal microscopy images
immunolabeled from Non-Tg (A,C) and 3xTg-AD mice (B,D) stained with
anti-Aβ40 (A,B) and anti-Aβ42 (C,D). The asterisks show the blood vessels
staining and arrowheads show the cytoplasmic staining of CP epithelial cells
(CP-EP) of lateral ventricle (LV). According to figure (see also the results in
text) in the left bottom (E) is also shown a scheme about the distribution of
Aβ40 and Aβ42 in vessels (V), stroma (ST) and epithelial cells (EP) of 3xTg-AD
compared to Non-Tg mice. On the right bottom (F) are presented values of
stain intensitites for Aβ40 and Aβ42 as the means ± SEM; n = eight animals
per group; * p < 0.01 3xTg-AD vs. Non-Tg mice. Scale bars, 30 µm.
DISCUSSION
3xTg-AD mice at 16 months exhibits age- related pathology
similar to human AD (Oddo et al., 2003b). We analyzed: (i) the
amount of Aβ fragment material in CP as well as the transporters
that move Aβ into and out of CP, (ii) the expression of collagen
at transport interfaces within the BCSFB; and (iii) the effects of
highly-expressed human AD-linked transgenes on the synthesis
of CP functional proteins such as TTR and AQP-1.
CHOROID EPITHELIAL CELL Aβ
Aβ accumulates in CP of AD patients. Similarly, we found
increased Aβ42 in epithelial cytoplasm of 3xTg-AD mice. Choroid
cell Aβ is also elevated in aging rats, various Tg mouse models
of Aβ, and in Pb-treated mice. Changes in CP Aβ levels reflect
altered homeostatic transport across the BCSFB and/or greater
local synthesis of Aβ in choroid cells. Excess Aβ in CP probably
alters homeostatic functions of the BCSFB (e.g., increased
barrier permeability) or compromises organic molecule transport
adjustments to protect the CSF-brain interstitial environment.
Toxic levels of Aβ in CP could potentially alter enzymatic
reactions that carry out homeostatic functions such as forming
CSF. Therefore, attention needs to be paid to Aβ loading (burden)
in CP as well as brain.
Aβ TRANSPORTERS IN CP
In the 3xTg-AD mice, we found increased LRP1 and RAGE in
CP cytosol. AQP-1 moves between cytosol and external limiting
membranes (e.g., apical) of CP to control functional activity
(Kalani et al., 2012); also, LRP1 and RAGE in cytosol probably
inserts into cellular membranes -also needing elucidation is
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FIGURE 2 | CP confocal microscopy images immunolabeled from
Non-Tg (A,C) and 3xTg-AD mice (B,D) stained with anti-LRP1 (A,B)
and anti-RAGE (C,D). An increase in cytoplasmic expression of LRP1 and
RAGE in epithelial cells of lateral ventricle (LV) of 3xTg-AD compared to
Non-Tg mice is shown. On the left bottom (E) are represented values of
stain intensitites for LRP1 and RAGE as the means ± SEM; n = eight
animals per group; * p < 0.01 3xTg-AD vs. Non-Tg mice. Scale bars,
30 µm.
how cytosolic transport proteins insert into organelles to
control Aβ metabolism and trafficking within the cell-. Clearly,
substantial Aβ data for BBB indicate that expression levels
of endothelial LRP1, LRP2, P-gP and RAGE markedly affect
Aβ burden in cortex. Similar transport/distribution principles
apply to BCSFB, in regard to clearing excess Aβ out of
CNS.
There is increased transcription of the Aβ efflux membrane
transporters, LRP1 and P-gp, no change in RAGE expression and
a decrease in Megalin/LRP2 at the BCSFB during normal aging
in rodents (Pascale et al., 2011). Although aging CP transport
phenomena mimics those of AD, they may differ in degree of
affectation. Age- dependent alterations in CP Aβ transporters
were associated with decreased Aβ42 in CP, and were reciprocal to
corresponding changes in LRP1 and PgP transporter expression
at the aging BBB (Silverberg et al., 2010a,b). This suggests
compensatory clearance via BCSFB of Aβ in aging, even as
the BBB LRP1 and P-gp transporters are failing (Pascale et al.,
2011).
Contrary to non-diseased aging, we found in 3xTg-AD
mice elevated Aβ42 and increased expression of cytosolic
LRP1 in CP epithelium (Figures 2B,E). Popular animal models
of AD, including 3xTg-AD, are mice overexpressing human
genes with mutations that cause familial AD. These Tg
mice overaccumulate Aβ in CP and brain. Aβ42 is more
problematic because it aggregates and promotes deposits earlier
in disease than Aβ40 (Iwatsubo et al., 1994). Thus, abundant
in brain are Aβ40 and Aβ2, the first being the prevalent
fragment, and the latter more amyloidogenic (Abramowski et al.,
2012).
Aβ UPTAKE FROM CSF BY CP
CP is contiguous with CSF and cerebral interstitial fluid
(ISF; Johanson, 2003). Thus, Aβ in brain ISF freely enters
CSF (Gu et al., 2014) and flows/diffuses to nearby CP for
reabsorption into choroidal venous blood. Moreover, interstitial
Aβ drainage from brain to ventricles seems to be the major
origin of Aβ in CSF because changes in CSF Aβ levels reflect
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FIGURE 3 | CP immunohistochemistry images from Non-Tg (A,B) and
3xTg-AD mice (C,D) show CP basement membrane and basal
membrane of CP vessels (V) immunostained with anti-collagen-IV
(arrows). (B,D) are enlarged images of (A,C) respectively. An increased
collagen-IV expression in CP of 3xTg-AD (C,D) compared to Non-Tg mice
(A,B) is shown. On the left bottom are represented values of stain
intensities for collagen-IV (E) as the means ± SEM; LV: lateral ventricle; n =
eight animals per group; * p < 0.01 3xTg-AD vs. Non-Tg mice. Scale bars,
60 µm.
changes in brain Aβ following therapeutic treatments (Lu
et al., 2013). CP epithelium is exposed to several-fold higher
Aβ40 concentrations in CSF than that of Aβ42 (Cirrito et al.,
2003; Head et al., 2010; Borghys et al., 2014; Savage et al.,
2014).
LRP1 in CP has a major role in removing Aβ from CSF
via clearance transport at the apical membrane. Why does
Aβ42 accumulate in cytosol near the apical membrane? Upon
transport into the choroid cell from CSF, there is probably
epithelial metabolism of cytoplasmic Aβ40 (Crossgrove et al.,
2007) and/or efflux at the choroid cell-ISF interface into venous
blood (Crossgrove et al., 2005). More needs to be known
about efflux transport in the basolateral membrane because this
is the final step in disposing CNS-CSF Aβ into blood, thus
protecting CP epithelium and ultimately the brain from Aβ
toxicity. In acute Pb-toxicity model, the decreased expression
of LRP1 in CP epithelium was associated, paradoxically, with
increased Aβ in CP (Behl et al., 2010); however, CP Aβ efflux
into blood was uncharacterized; a factor also affecting epithelial
Aβ concentration.
METABOLIC PROCESSING OF CP Aβ
Following uptake of Aβ from outside CP, or its enzymatic
generation within the epithelium, there is processing of the
amyloid peptides to minimize toxicity. Low solubility and
elevated Aβ42 in CP may exceed lysosomal degradation capacity.
Notably, intact lysosomes are more prevalent in fluorescein-
labeled Aβ0 (F-Aβ40) treated cells than in F-Aβ42 treated
cells, likely due to less F-Aβ40 inability to accumulate in
lysosomes (Omtri et al., 2012). Cell culture reveals substantial
intracellular Aβ and comparably little secretion, particularly of
Aβ42 (Maruyama et al., 1995). Moreover, continuous uptake
data suggest that, over time, Aβ42 might escape degradation and
start to accumulate (Fuentealba et al., 2010). All in all, CP Aβ
accumulation is a function of Aβ metabolism as well as uptake
from CSF.
Our current study shows significantly reduced Aβ40 in
CP epithelium and stroma in 3xTg-AD vs. Non-Tg mice
(Figures 1A,B,F). Aβ40 impacts lysosomal integrity less because
of smaller propensity to aggregate and greater susceptibility to
lysosomal proteases. Aβ40 clears rapidly after i.c.v. injection
(Ghersi-Egea et al., 1996; Ji et al., 2001), and may also be degraded
faster in CP. Interestingly, in Tg mouse lines generating Aβ40
(APP47) and Aβ42 (APP48) in neurons, APP47 mice only show
somatic Aβ granules consistent with a more rapid, complete
degradation of Aβ40 (Omtri et al., 2012).
Our findings provide evidences CP internalize Aβ40 and
Aβ42 via different mechanisms. Such regulated trafficking
along distinct pathways suggests that Aβ40 and Aβ42 exercise
differential effects on CP epithelial cells. Further studies should
investigate the intracellular pharmacokinetics of Aβ40 and Aβ42
following uptake at the BCSFB, and evaluate the tendency of Aβ
fragments to accumulate in cellular compartments susceptible to
Aβ toxicity.
DO PLASMA INCREASED Aβ AND SOLUBLE LRP1 ALSO AFFECT CP-CSF
Aβ?
Aβ may enter CP from plasma as well as CSF. We show increased
choroid cell Aβ42 immunofluorescence, punctuated in CP of
3xTg-AD compared with Non-Tg mice (Figures 1C,D,F). In
neurologically-healthy humans and mice, a soluble LRP1 species,
sLRP1, binds >70% of vascular-circulating Aβ; this prevents
free Aβ access to brain (and presumably CP epithelium; Sagare
et al., 2007). In AD patients and Tg mice, Aβ binding to sLRP1
is severely compromised. This results in elevated levels of free
Aβ40 and Aβ42 in plasma (Sagare et al., 2011) that (in addition
to LRP1-mediated Aβ efflux into blood) can re-enter brain via
RAGE transport across BBB, and possibly CP (Deane et al., 2003;
Donahue et al., 2006; Sagare et al., 2007).
RAGE transports Aβ into CNS from plasma, where it may be
elevated in AD (Deane et al., 2003). RAGE expression increases
in neurons, astrocytes and cerebrovascular endothelial cells in an
Aβ-rich environment, seen in AD models and dementia (Deane
et al., 2003; Choi et al., 2014). Such influx, if accelerated by
elevated plasma Aβ via upregulated RAGE in BBB and BCFSB,
would amplify the Aβ-mediated pathogenic/metabolic responses.
Our study does show increased cytosolic RAGE expression in
CP epithelial cells and an Aβ42 increase in CP stroma of
3xTg-AD vs. Non-Tg mice (Figures 2D,E). Similarly to BBB,
Aβ42 accumulation in CP blood and stroma may induce a
RAGE increase, which could lead to a significant Aβ increase in
CP.
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FIGURE 4 | CP confocal images immunolabeled from Non-Tg (A,C) and
3xTg-AD mice (B,D) stained with anti-TTR (A,B) and anti-AQP-1 (C,D). A
reduction in cytoplasmic expression of TTR (A,B) as well as in AQP-1
expression in the apical membrane of epithelial cells (C,D) is shown in
3xTg-AD when compared to Non-Tg mice (arrowheads). The arrows in (D)
indicate areas where AQP1 was not detected on the apical membrane of CP
epithelium. On the left bottom side are represented values of stain
intensitites for TTR and AQP-1 (E) as the means ± SEM; LV: lateral ventricle;
n = eight animals per group; * p < 0.01 3xTg-AD vs. Non- Tg mice. Scale
bars, 30 µm.
ALTERED BASEMENT MEMBRANES IN THE BCSFB AND BBB OF
3xTg-AD MICE
The basement membrane (Deane et al., 2004) thickens in
the BBB of 3xTg-AD mice; this thickening can modulate
hemodynamic responses, microvessel integrity/permeability and
molecular fluxes via transporter expression/activity in the barrier.
Animal models reveal mechanisms that link reduced cerebral
blood flow (CBF) to capillary state. Permanently ligated common
carotid arteries in rats model chronic cerebral hypoperfusion,
when CBF is reduced to ∼70% (Tsuchiya et al., 1992). This
coincides with falling CBF in the hippocampus and temporal
cortex in AD (Eberling et al., 1992; Ohnishi et al., 1995; Tang et al.,
2012; Mattsson et al., 2014). A previous 3xTg-AD study described
reduced vascular volume in brain of 11-month-old mice; BBB
functional integrity was maintained even though reduced vascular
volume was accompanied by accumulated collagen I/IV and a
thickened vascular basement membrane (BM; Bourasset et al.,
2009). Microvascular BM thickening, with more collagen-IV, has
been also shown in human AD (Kalaria and Pax, 1995; Claudio,
1996); pathophysiologic analyses of transporters and fluxes in
thickened BBB membranes need to be done.
CP is highly perfused, much greater than brain. Any
dwindling of this brisk choroidal blood flow, as in AD,
might impact endothelial cells and their underlying BM. In
the current study, the apparent thickness of BM in CP
was assessed immunohistochemically by measuring collagen-
IV (Farkas and Luiten, 2001). For the first time, we show
significantly accumulated collagen-IV in BM of CP in 3xTg-AD
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mice (Figures 3C–E). The exact reason for increased collagen-IV
and subsequent thickening of the BMs in AD, at both the capillary
and epithelial BMs, needs full characterization. According to
Fick’s diffusion theory, a major factor affecting diffusion across
biological membranes is membrane thickness. BM thickening
reduces permeability (Zwolinski et al., 1948) and makes plasma
ultrafiltration, CP epithelial oxygenation and CSF formation all
less efficient. This idea fits our findings of lower expression of
AQP-1 and TTR in CP in 3xTg-AD mice.
CSF BULK FLOW ATTENUATION: REDUCED EXCRETION OF CSF Aβ
Along with reduced clearance of Aβ across BBB with increasing
age and AD, there is also a decline in Aβ clearance from CNS
via CSF bulk flow into the arachnoidal-venous system (Silverberg
et al., 2010b; Pascale et al., 2011; Serot et al., 2011). What
mechanisms underlie this phenomenon? CSF formation by CP,
and its eventual turnover into the ventriculo-subarachnoid CSF
system, depends upon the molecular integrity of CSF- transport
enzymes and AQP-1; the expression of both are reduced in 3xTg-
AD mice, probably by toxic levels of Aβ in CP. Our working
model supports the notion that accumulating Aβ42 in choroidal
epithelium contributes to a dysfunctional BCSFB. In fact, a
sequence of pathological steps that link Aβ accumulation with an
AD progression-related increase in oxidative damage, has recently
been proposed (Krzyzanowska and Carro, 2012).
The necessarily high water permeability of the CP interface
is made possible, in part, by AQP-1, a water channel expressed
strongly at the ventricular- facing surface (Boassa and Yool,
2005). Senescent rats are less able to form CSF (Masseguin et al.,
2005); a reduced AQP-1 expression in CP accompanies slower
rates of CSF secretion in aging (Redzic et al., 2005). Similarly,
reduced CSF secretion occurs in aging and AD (Johanson et al.,
2008; Chen et al., 2009; Serot et al., 2012). The reduced AQP-
1 expression in CP of 3xTg-AD mice (Figures 4C–E) probably
impairs CP capacity to secrete CSF; consequently, the slowing of
CSF convection would reduce Aβ removal from 3xTg-AD mice
CNS via ventricular bulk flow.
LOWER EXPRESSION OF CP TRANSTHYRETIN: IMPLICATIONS FOR
REDUCED Aβ REMOVAL
Decreased CP protein synthesis/secretion as well as slower
CSF renewal accelerate the progressing neuropathology. As
mentioned, some CP proteins interact neuroprotectively with Aβ
and this could be the basis for altered Aβ clearance; lower TTR
in CSF would mean less neuroprotection afforded via enzymatic
degradation of Aβ and tetramer stabilization binding. TTR is a
major protein synthesized and secreted by CP into CSF (Dickson
et al., 1986); this tetrameric protein binds to and stabilizes soluble
Aβ (Tang et al., 2004). We found reduced TTR expression in
CP of 3xTg-AD vs. Non-Tg mice (Figures 4A,B,E). Lower TTR
expression in CP of 3xTg-AD mice likely leads to deficiency
of TTR in CSF. Decreased CSF levels of TTR occur in severe
dementia and AD (Riisøen, 1988; Serot et al., 1997). Since CP
is the primary source of TTR in the CNS, a CSF-deficient
TTR presumably results from decreased CP synthesis/secretion in
aging and AD (Stoquart-ElSankari et al., 2007). Diminishing CNS
TTR has been linked to cognitive decline with age (Preston et al.,
2005). A key question is whether excess Aβ in CP directly down-
regulates TTR expression in epithelial cells.
CONCLUSIONS
Our findings prompt consideration of identifying ways to protect
or restore the gradually-failing functions of the BCSFB in the face
of metabolic dysfunctions in the aging, diseased CNS. A healthy
CP in advanced life stages would confer numerous benefits
on the brain. Moreover, these results may be considered for
futures pharmacological treatments in order to restore impaired
functions of CP in AD.
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